Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment

ConclusionsThis study proposes BFSigs as a biomarker for the effective selection of apoptosis targeting treatments and cancer pathways to co-target in AML.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research